In addition to psoriasis and psoriatic arthritis, IL-17A blockade has also shown preclinical and clinical efficacies in ankylosing spondylitis and rheumatoid arthritis15, 16, 17, 18, 19, 20. Here, IL17A is linked to psoriatic arthritis.